… (MDR) proteins expressed in AML cells. We also tested … bortezomib interactions with
cytarabine and anthracyclines are affected by p53, because proteasome inhibition stabilizes p53 …

… (MDR) proteins expressed in AML cells. We also tested … bortezomib interactions with
cytarabine and anthracyclines are affected by p53, because proteasome inhibition stabilizes p53 …

… anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug
resistance mechanisms and p53 status. Cancer Chemother Pharmacol 60: 245-255, 2007. …

… However, bortezomib has limited single-agent activity in … bortezomib interacts synergistically
with anthracyclines and/or … cells are independent of multidrug resistance mechanisms …

… pattern as well as for combination experiments, cytarabine, cisplatin, … as well as tubulin-associated
multi-drug resistance. … in vitro data indicate that bortezomib activity is independent …

… In the HL60 line, inhibited by FTI and bortezomib independently, the combination did not …
bortezomib cytotoxicity or in vitro interactions with anthracyclines or cytarabine (Citation26). …

… (often cytarabine [Ara-C] in combination with an anthracycline, such … This so-called multi-drug
resistance (MDR) is a major … , in combination with bortezomib can effectively overcome this …

… Of note, the use of proteasome inhibitors, such as bortezomib… of mutation affecting prognosis,
being related to anthracycline … Multidrug resistance (MDR) efflux transporters of the ABC (…

… Primary human acute myeloid leukemia (AML) and chronic … of 5AHQ cell viability and
proteasome activity in K562 cells, … multidrug resistance drug efflux transporters that can confer a …

… Chemotherapy with cytarabine (AraC) and an anthracycline … independent drug resistance
model of doxorubicin-resistant … that bortezomib treatment could overcome drug resistance in …